Vaccinex Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VCNX Nasdaq 8731 https://www.vaccinex.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vaccinex Inc

Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET - Jun 1st, 2023 12:00 pm
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update - May 15th, 2023 8:45 pm
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab - Apr 25th, 2023 12:00 pm
Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells - Apr 12th, 2023 12:00 pm
Vaccinex Announces Private Placement with Commitments of $5.0 Million - Apr 3rd, 2023 12:30 pm
Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in Neurology and Oncology Clinical Programs - Apr 3rd, 2023 12:00 pm
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference - Mar 23rd, 2023 12:00 pm
Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) - Mar 21st, 2023 12:30 pm
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis - Mar 9th, 2023 1:00 pm
The 3 Best Biotech Stocks Under $1 to Buy for January - Jan 26th, 2023 11:06 pm
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology - Jan 9th, 2023 1:00 pm
13 Best Biotech Penny Stocks To Buy Now - Nov 29th, 2022 10:43 pm
Vaccinex Announces $3.8 Million Private Placement - Nov 28th, 2022 1:00 pm
Vaccinex Third Quarter 2022 Earnings: US$0.11 loss per share (vs US$0.17 loss in 3Q 2021) - Nov 16th, 2022 10:38 am
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update - Nov 14th, 2022 1:30 pm
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer - Nov 10th, 2022 2:00 pm
Companies Like Vaccinex (NASDAQ:VCNX) Could Be Quite Risky - Nov 3rd, 2022 10:16 am
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs - Aug 15th, 2022 12:10 pm
Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation - Aug 8th, 2022 3:00 pm
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease - Jul 29th, 2022 11:00 am